# Allergy Therapeutics is poised for a transformational period of growth

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-poised-transformational-period-growth/412755033
- Published: 2018-07-19T07:15:52+01:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical company specialising in allergy vaccines,
announced today a placing and subscription of up to 40,000,000 new ordinary shares
of 0.1 pence each in the capital of the Company, representing up to approximately
6.7% of the Company’s existing ordinary share capital, to raise up to £10.6 million.

**Highlights**

· Placing and subscription of up to 40,000,000 New Shares in the Company, representing
up to approximately 6.7% of the Company’s existing ordinary share capital, at a 
price of 26.5 pence per New Share to raise up to approximately £10.6 million before
expenses.

· The Company intends to use the Placing and Subscription proceeds to expand the
planned Phase III PQ Grass Trial, part fund the Acarovac Phase II Trial and continue
to progress its diversified pipeline.

· Revenue for the financial year ended 30 June 2018 is expected to be £68.3 million(
2017: £64.1 million). This represents a 6.6% annual growth on a reported basis and
3.5% on a constant currency basis despite the unusually weak pollen season in 2017.
The Company is also continuing to gain market share within its core markets in Europe
and data for the key markets for the 9 months ended 31 March 2018 showed an increase
of 0.7 of a market share point[1].

The Placing is being conducted through an accelerated bookbuilding process which
will commence immediately in accordance with the terms and conditions set out in
Appendix I to this Announcement.

Panmure Gordon (UK) Limited is acting as Financial Adviser, Nominated Adviser and
Corporate Broker in respect of the Placing.

> **Manuel Llobet, Chief Executive Officer, stated:** “Allergy Therapeutics is poised
> for a transformational period of growth both with our marketed products and our
> R&D pipeline. With this planned funding, we hope to expand our planned Phase III
> PQ Grass trial, scheduled to start in H2 2019, including a project to analyse 
> pollen trends in the US to maximise the exposure of patients to grass pollen. 
> We also intend to support the Acarovac Phase II trial and, looking further out,
> further progress our diversified pipeline of patient friendly, convenient to use
> products including Polyvac Peanut.”

**Background to the Placing and Subscription**

Allergy Therapeutics is an international commercial biotechnology company focused
on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy
vaccines that have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in eight major European countries and
via distribution agreements in an additional fourteen countries. Its broad pipeline
of products in clinical development include vaccines for grass, tree and house dust
mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in development.

In a trading update for the year ended 30 June 2018, the Company reported that revenues
for the year are expected to be in line with market expectations at £68.3 million(
2017: £64.1 million). This performance represents 6.6% annual growth on a reported
basis and 3.5% on a constant currency basis which reflects a strong performance 
during an unusually weak pollen season in 2017. The Group is continuing to gain 
market share within its core markets in Europe and data for the key markets for 
the nine months ended 31 March 2018 showed an increase of 0.7 of a market share 
point[2].

The Company is making continual advances across all three of its major strategic
objectives; profitably expanding the existing European business; preparing for product
entry into the US market; and developing a strong product pipeline.

The European business of Allergy Therapeutics has grown at a CAGR of 10% over the
last 19 years from its flexible and varied product portfolio. Recently, the Company
reported annual growth of 3.5% and increased its market share by 0.7 of a market
share point[3] which is the result of:

· Innovative, convenient and patient-friendly (short-course) products;

· Increased regulatory requirements which has resulted in 40% of all the products
that were on the market and submitted for the TAV process dropping out and no longer
being allowed to be sold in Germany[4];

· Focused investment across the business;

· Strength of a broad portfolio with modified house dust mite and venom SCIT; and

· Scaling-up to drive technological and geographical expansion.

The Directors believe that the US allergy immunotherapy market is estimated to be
valued at $2 billion and, of that market, estimated peak grass sales could be $300-
400 million. There are no registered injected products and adherence levels to treatments
are as low as 15%[5]. The changing US regulatory landscape provides an opportunity
for Allergy Therapeutics. New United States Pharmacopeia and US Food and Drug Administration
regulations are moving to pharmaceutical grade, centrally manufactured, single allergen
treatments. Existing products in the market are long courses of treatment with between
50-100 injections with efficacy in 6-12 months. Allergy Therapeutics can offer a
short course treatment of 4-6 injections with efficacy in three weeks for a four
shot treatment plan.

Allergy Therapeutics is progressing its Birch Phase III trial for Europe, the results
of which are expected in Q3 2018. The Phase III field trial in Europe recruited 
582 patients from 59 centres in Germany, Austria, Poland and Sweden. The trial is
a double blind placebo controlled trial and is pivotal for approval in Germany. 
If the trial is successful and approved, the next step is expected to lead to a 
market authorisation.

On 21 May 2018, the Company announced positive top-line results from its grass modified
allergen tyrosine absorbed MPL Phase II dose ranging study. The trial met its primary
endpoint of establishing a dose-response relationship and a Phase III dose. The 
trial, conducted on 447 patients in 50 sites in Germany, Austria and Poland, measured
four aspects of eye symptoms to generate a total symptom score.

Acarovac, the Company’s Mite MPL house dust mite product, is currently undergoing
its Phase I trial with the results expected in H1 2019. Acarovac is a short-course
product that can be used to address the potential market of $3 billion[6] worldwide
with only Europe partially covered already. In the Company’s preclinical pipeline,
its Polyvac peanut product offers a potential solution to the $8 billion[7] worldwide
food allergy market. The single dose of VLP combined with recombinant peanut allergen
successfully protects against anaphylaxsis when challenged with peanut. Polyvac 
Peanut received positive results from its pre-clinical research and pre-clinical
development has been progressing according to plan with important product differentiation
demonstrated. The Company signed a manufacturing contract for scale-up of the Polyvac
product with the aim of having the first trial in humans in 2019.

**Reasons for the Placing and Subscription and Use of Proceeds**

The Directors believe that Allergy Therapeutics has the opportunity to accelerate
growth across its three pillars of growth outlined above. Allergy Therapeutics is
seeking to raise up to £10.6 million via the Placing and Subscription, earmarked
for investment by the Company in:

· expanding the planned Phase III PQ Grass trial, scheduled to start in H2 2019.
The Phase III trial will entail an increase in the number of patients recruited 
to the study, the introduction of a vaccinated placebo arm (following the completion
of the trial, to reduce the overall cost of the potential safety database), and 
an additional project to analyse pollen trends in the US to maximise the exposure
of patients to grass pollen;

· part funding of the Acarovac Phase II trial (balance of funding for trial from
CDTI to start, subject to contract, in 2019); and

· ensuring continued progress on a diversified pipeline, including developing the
Polyvac Peanut product.

**Details of the Placing and Subscription**

The New Shares are to be allotted and issued by the Company pursuant to the Directors’
existing authority to allot Ordinary Shares for cash on a non-pre-emptive basis 
approved by shareholders at the Company’s annual general meeting held in 2017. The
Placing will be effected by way of a bookbuilding process to be managed by Panmure
Gordon and will be conducted in accordance with the terms and conditions set out
in Appendix I. The Bookbuild will commence with immediate effect and the book is
expected to close no later than 4.30 p.m. today, 19 July 2018, although Panmure 
Gordon reserves the right to close the book earlier, without further notice. The
Company has received non-binding indications of interest from potential institutional
investors for the Placing and Subscription during a pre-marketing process. The timing
of the closing of the book and allocations is at the absolute discretion of Panmure
Gordon. The Placing and Subscription will be limited to the subscription of up to
40,000,000 New Shares, representing up to approximately 6.7% of the Company’s existing
ordinary share capital at the Issue Price. The number of New Shares will be agreed
by the Company with Panmure Gordon at the close of the Bookbuild. Details of the
number of New Shares will be announced as soon as practicable after the close of
the Bookbuild.

The New Shares will, when issued, be credited as fully paid and will rank pari passu
in all respects with the existing ordinary shares of the Company, including the 
right to receive all dividends or other distributions made, paid or declared in 
respect of such shares after the date of issue of the New Shares.

The Placing is conditional, inter alia, upon:

i. admission of the New Shares to trading on AIM becoming effective (“Admission”);

ii. the Subscription Agreement becoming unconditional in accordance with its terms(
save for any condition relating to Admission) and the subscription funds being received
by the Company prior to Admission; and

iii. the Placing Agreement between the Company and Panmure Gordon not being terminated
prior to Admission.

The Subscription is conditional, inter alia, upon the Placing Agreement becoming
wholly unconditional in accordance with its terms and not being terminated, and 
Admission having occurred.

Application will be made to the London Stock Exchange for the New Shares to be admitted
to trading on AIM and it is expected that Admission will become effective and that
dealings in the New Shares will commence at 8.00 a.m. on or around 25 July 2018.

Share on:
